Literature DB >> 19562755

N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42.

Cristina D'Arrigo1, Massimo Tabaton, Angelo Perico.   

Abstract

We tested directly the differences in the aggregation kinetics of three important beta amyloid peptides, the full-length Abeta1-42, and the two N-terminal truncated and pyroglutamil modified Abetapy3-42 and Abetapy11-42 found in different relative concentrations in the brains in normal aging and in Alzheimer disease. By following the circular dichroism signal and the ThT fluorescence of the solution in phosphate buffer, we found substantially faster aggregation kinetics for Abetapy3-42. This behavior is due to the particular sequence of this peptide, which is also responsible for the specific oligomeric aggregation states, found by TEM, during the fibrillization process, which are very different from those of Abeta1-42, more prone to fibril formation. In addition, Abetapy3-42 is found here to have an inhibitory effect on Abeta1-42 fibrillogenesis, coherently with its known greater infective power. This is an indication of the important role of this peptide in the aggregation process of beta-peptides in Alzheimer disease. (c) 2009 Wiley Periodicals, Inc. Biopolymers 91: 861-873, 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562755     DOI: 10.1002/bip.21271

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  26 in total

Review 1.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.

Authors:  Roxanna Perez-Garmendia; Vanessa Ibarra-Bracamontes; Vitaly Vasilevko; Jose Luna-Muñoz; Raul Mena; Tzipe Govezensky; Gonzalo Acero; Karen Manoutcharian; David H Cribbs; Goar Gevorkian
Journal:  J Neuroimmunol       Date:  2010-09-22       Impact factor: 3.478

3.  Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.

Authors:  Christopher P Sullivan; Eric A Berg; Rosemary Elliott-Bryant; Jordan B Fishman; Ann C McKee; Peter J Morin; Michael A Shia; Richard E Fine
Journal:  Neurosci Lett       Date:  2011-10-06       Impact factor: 3.046

4.  Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.

Authors:  Christina Dammers; Kerstin Reiss; Lothar Gremer; Justin Lecher; Tamar Ziehm; Matthias Stoldt; Melanie Schwarten; Dieter Willbold
Journal:  Biophys J       Date:  2017-04-25       Impact factor: 4.033

Review 5.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

Review 6.  Implications of peptide assemblies in amyloid diseases.

Authors:  Pu Chun Ke; Marc-Antonie Sani; Feng Ding; Aleksandr Kakinen; Ibrahim Javed; Frances Separovic; Thomas P Davis; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

7.  Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.

Authors:  Adam P Gunn; Bruce X Wong; Timothy Johanssen; James C Griffith; Colin L Masters; Ashley I Bush; Kevin J Barnham; James A Duce; Robert A Cherny
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

8.  Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.

Authors:  Markus Morawski; Maike Hartlage-Rübsamen; Carsten Jäger; Alexander Waniek; Stephan Schilling; Claudia Schwab; Patrick L McGeer; Thomas Arendt; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2010-04-10       Impact factor: 17.088

9.  Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides.

Authors:  Greg Goldblatt; Jason O Matos; Jeremy Gornto; Suren A Tatulian
Journal:  Phys Chem Chem Phys       Date:  2015-12-28       Impact factor: 3.676

10.  Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias.

Authors:  Anika Saul; Tammaryn Lashley; Tamas Revesz; Janice Holton; Jorge A Ghiso; Janaky Coomaraswamy; Oliver Wirths
Journal:  Neurobiol Aging       Date:  2012-12-20       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.